IART logo

INTEGRA LIFESCIENCES HOLDING

IARTNASDAQ
πŸ† #1824 by market capEarnings Oct 29US Equity
$17.37β–² $0.31 (+1.76%)
Market closed Β· at close
1hβ€”
24hβ–² 1.8%
7dβ–Ό 1.8%
14dβ–² 6.3%
30dβ–Ό 6.6%
1yβ–² 26.1%
🏦Market Cap
$1.35B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+1.5%
Slowing
πŸ“ŠGross Margin
53.7%
Healthy
πŸ’΅FCF Margin
2.4%
Thin
βš–οΈP/S Ratio
0.8x
Cheap
Otter Score
65
Fair

Trading Snapshot

Day Range
$17.17 – $17.59
52-Week Range
$8.70 – $20.49
Volume
$2.02B
Avg Volume
$2.25B
Shares Outstanding
77.8M
Next Earnings
Sep 4, 2026

Fundamentals Snapshot

Annual Revenue
$1.64B
Last Q Revenue
$419M
P/E Ratio
-188.4
P/S Ratio
0.8x
EPS (TTM)
$-0.09
Dividend Yield
0.00%

Why Investors Own IART

  • βœ“High-growth profile β€” revenue up +31.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 79% gross margin and 23% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$1.64Bβ–² +27.2% YoY
Gross Margin (TTM)
79.0%β–² +3.6% YoY
Operating Income (TTM)
$448Mβ–² +27.2% YoY
Free Cash Flow (TTM)
$373Mβ–² +27.2% YoY

About INTEGRA LIFESCIENCES HOLDING

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
65/100

Analyst Price Target

β“˜
Average Target
$22.94
β–² +32.1% Upside
High Target$24.88
Low Target$17.65
Based on 23 analysts

Latest News & Updates